The U.S. Food and Drug Administration has released draft guidance aimed at helping drug developers validate non-animal testing methodologies. This initiative supports the agency's ongoing efforts to modernize drug development, reduce reliance on animal models, and promote the adoption of innovative, scientifically sound alternatives in the pharmaceutical industry.
A two-day industry meeting has commenced in Moscow, bringing together representatives from India and the Russian Federation to enhance bilateral trade and deepen cooperation within the pharmaceutical sector. The discussions aim to address supply chain resilience and explore new opportunities for joint ventures in drug manufacturing and research.
Health ministers from Russia and Egypt held high-level talks in Moscow to bolster bilateral ties in the medical and pharmaceutical sectors. The discussions focused on expanding collaboration in drug production, medical technology, and public health initiatives to enhance healthcare accessibility in both nations.
The U.S. Food and Drug Administration has introduced a new, unified platform designed to modernize the reporting and monitoring of adverse events for regulated products. This initiative aims to streamline data collection, improve safety surveillance, and enhance the agency's ability to identify and respond to potential health risks associated with FDA-regulated items.
The Irish Fiscal Advisory Council (IFAC) has reported that three multinational companies contributed 46% of Ireland's corporate tax in 2024, amounting to approximately €13 billion. This highlights the country's increasing reliance on a small number of firms for a significant portion of its public revenue, raising concerns about fiscal stability.
A significant majority of UK pharmacies, particularly in England, are reportedly at risk of imminent closure due to severe financial pressures. Industry bodies warn that underfunding, rising costs, and a reliance on personal savings are jeopardizing essential patient services.
Arrotex Pharmaceuticals and Pfizer Australia have forged a new strategic commercial partnership for the distribution of ENBREL (etanercept) across Australian pharmacy channels, effective February 1, 2026. This collaboration aims to enhance access to the biologic therapy for autoimmune conditions.
Martin Holst Lange, Novo Nordisk's Executive Vice President for R&D and Chief Scientific Officer, sold 22,000 B shares on Nasdaq Copenhagen for DKK 7,035,600 on February 9, 2026. The sale was conducted to cover tax liabilities arising from shares received under the company's long-term incentive program, in line with EU market abuse regulations.
Bayer's investigational drug, Asundexian, a Factor XIa inhibitor, has shown significant efficacy in reducing the risk of recurrent ischemic stroke by 26% in the pivotal Phase III OCEANIC-STROKE trial. The study, presented at the International Stroke Conference 2026, also confirmed no increase in major bleeding events, offering a potential new option for secondary stroke prevention.
Medicines Australia has called on the Federal Government to prioritize investment in innovative medicines and implement critical Health Technology Assessment (HTA) reforms in the 2026-27 Budget. The organization highlights Australia's significant lag in patient access to new treatments compared to other OECD nations, citing average delays of over a year for PBS listing.
AstraZeneca has announced a significant licensing agreement with China's CSPC Pharmaceutical Group for experimental obesity and weight-related drugs. The deal involves an upfront payment of $1.2 billion and up to $17.3 billion in milestones, granting AstraZeneca global rights outside Greater China to eight drug programs, including the clinical-ready SYH2082.
Johnson & Johnson has entered into a voluntary drug-pricing agreement with the Trump administration, becoming the 15th pharmaceutical company to do so. The deal aims to lower drug costs and improve access for American patients through 'Most-Favored-Nation' pricing, participation in TrumpRx.gov, and tariff exemptions, alongside J&J's $55 billion U.S. investment commitment.
The UK government is rolling out significant reforms in 2026 to enhance its appeal for clinical trials, aiming to accelerate patient access to new treatments and bolster its global competitiveness. Key changes include faster assessment pathways, a new fast-track route for lower-risk studies, and an extended retention period for trial records.
Japan's Liberal Democratic Party and Japan Innovation Party have agreed to cut national medical costs by 188 billion yen annually, starting next fiscal year. The plan involves revising drug insurance coverage, including additional patient payments for certain prescription medicines similar to over-the-counter drugs.
President Trump announced new agreements with nine leading pharmaceutical companies on December 19, 2025, to lower prescription drug prices for Americans. The deals involve 'Most-Favored-Nation' pricing for Medicaid and direct-to-consumer sales via TrumpRx.gov, aiming to align U.S. costs with global rates.
The United States and the United Kingdom have agreed to eliminate tariffs on pharmaceutical products, with the UK committing to a 25% increase in the net price paid for new medicines. This landmark deal, part of the broader UK-US Economic Prosperity Deal, aims to enhance access to innovative therapies, strengthen supply chains, and boost investment in the life sciences sector for both nations.
International sanctions, reimposed on Iran following the US withdrawal from the JCPOA, have led to critical shortages of life-saving medications. Despite humanitarian exemptions, banking restrictions and currency depreciation severely hinder the import of essential drugs and raw materials, impacting vulnerable patients across the country.
UK Science Minister Patrick Vallance has confirmed that officials are actively working to resolve a significant drug pricing dispute with major pharmaceutical companies. The row, centered on the Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), has led to several firms withdrawing or pausing substantial investments in the UK, impacting jobs, research, and patient access to new medicines.
Dr. Mikael Dolsten, formerly Pfizer's Head of R&D, withdrew his candidacy for Novo Nordisk's Board of Directors on November 13, 2025, citing personal reasons. His withdrawal occurred just before an Extraordinary General Meeting where a significant board overhaul was approved.
German radiopharmaceutical company ITM has received U.S. FDA Fast Track designation for its diagnostic agent, ITM-94, for the detection of clear cell renal cell carcinoma. This designation aims to expedite the development and review of the gallium-68-radiolabeled PET imaging agent, which targets carbonic anhydrase IX (CAIX) and addresses a high unmet medical need.
